NBTX revenueFY2025€32.59M
- 5Y CAGR
- +67.0%
NBTX revenue was €32.59M for fiscal 2025 (ended Dec 31, 2025), compared with -€7.19M in fiscal 2024. Compound annual growth was +67.0% over 5 years.
Nanobiotix S.A. (NBTX) financials
For fiscal 2025 (ended Dec 31, 2025), Nanobiotix S.A. reported €32.59M of revenue and -€23.96M of net income. Figures are in EUR, the currency of its SEC filings.
- Revenue, FY2025
- €32.59M
- Net income, FY2025
- -€23.96M
- Net margin
- -73.5%
- Free cash flow, FY2025
- -€33.96M
- EPS, diluted, FY2025
- -€0.50
- Cash
- €52.75M
FY2018FY2025
FY2018FY2025
FY2018FY2025
NBTX revenue and earnings growth
NBTX net incomeFY2025-€23.96M
NBTX net income was -€23.96M for fiscal 2025 (ended Dec 31, 2025), compared with -€68.13M in fiscal 2024.
NBTX EPSFY2025-€0.50
NBTX diluted EPS was -€0.50 for fiscal 2025 (ended Dec 31, 2025), compared with -€1.44 in fiscal 2024.
NBTX free cash flowFY2025-€33.96M
NBTX free cash flow was -€33.96M for fiscal 2025 (ended Dec 31, 2025), compared with -€20.40M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | €32.59M | -€7.19M | €36.21M | €4.78M | €2.65M | €2.51M | €2.54M | €3.48M |
| Research and development | €23.11M | €40.54M | €38.40M | €32.64M | €30.38M | €24.33M | €30.41M | €20.89M |
| Selling, general and admin | €20.36M | €20.53M | €22.05M | €17.86M | €19.43M | €14.61M | €18.91M | €12.65M |
| Operating income | -€10.82M | -€68.39M | -€26.78M | -€46.70M | -€52.58M | -€36.43M | -€46.78M | -€30.07M |
| Interest expense | €15.23M | €7.49M | €14.80M | €13.86M | €780.0K | -€2.65M | €4.97M | €847.0K |
| Pre-tax income | -€23.96M | -€68.13M | -€39.70M | -€57.04M | -€47.00M | -€33.59M | -€50.91M | -€30.34M |
| Income tax | €3.0K | €101.0K | €120.0K | €10.0K | €5.0K | €9.0K | €3.0K | €0 |
| Net income | -€23.96M | -€68.13M | -€39.70M | -€57.00M | -€47.06M | -€33.59M | -€50.91M | -€30.34M |
| EPS, basic | -€0.50 | -€1.44 | -€1.08 | -€1.64 | -€1.35 | -€1.38 | -€2.35 | -€1.55 |
| EPS, diluted | -€0.50 | -€1.44 | -€1.08 | -€1.64 | -€1.35 | -€1.38 | -€2.35 | -€1.55 |
| Diluted shares | 47.82B | 47.27B | 36.93B | 34.85B | 34.73B | 24.39B | 21.63B | 19.63B |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | €52.75M | €49.74M | €75.28M | €41.39M | €83.92M | €119.15M | €35.09M | €36.20M |
| Current assets | €62.75M | €61.47M | €87.34M | €52.36M | €93.06M | €125.25M | €46.13M | €42.54M |
| Total assets | €67.76M | €67.42M | €93.90M | €59.77M | €101.77M | €134.03M | €56.20M | €51.58M |
| Current liabilities | €57.51M | €58.94M | €49.87M | €37.94M | €36.84M | €19.04M | €14.35M | €12.15M |
| Total liabilities | €152.24M | €133.12M | €95.74M | €86.81M | €74.98M | €63.56M | €58.11M | €37.34M |
| Shareholders' equity | -€84.48M | -€65.70M | -€1.84M | -€27.05M | €26.79M | €70.47M | -€1.91M | €14.24M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -€33.42M | -€19.55M | -€12.48M | -€37.10M | -€29.87M | -€27.54M | -€41.17M | -€25.98M |
| Capital expenditures | €538.0K | €846.0K | €328.0K | €92.0K | €228.0K | €96.0K | €1.09M | €416.0K |
| Free cash flow | -€33.96M | -€20.40M | -€12.80M | -€37.20M | -€30.10M | -€27.63M | -€42.26M | -€26.40M |
| Investing cash flow | -€578.0K | -€955.0K | -€349.0K | €138.0K | -€242.0K | -€112.0K | -€1.46M | €71.0K |
| Financing cash flow | €37.42M | -€5.13M | €46.77M | -€5.65M | -€5.18M | €111.77M | €41.49M | €14.85M |
| Stock-based compensation | €3.54M | €4.30M | €3.22M | €3.17M | €3.20M | €2.92M | €4.32M | €1.87M |
| Depreciation and amortization | €1.50M | €1.62M | €1.51M | €1.50M | €1.56M | €1.75M | €1.77M | €619.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | -119.9% | 658.1% | 80.4% | 5.4% | -1.1% | -27.0% | - |
| Operating margin | -33.2% | - | -74.0% | -977.8% | -1986.4% | -1450.2% | -1841.0% | -864.2% |
| Net margin | -73.5% | - | -109.6% | -1193.5% | -1778.0% | -1337.2% | -2003.7% | -872.2% |
| Free cash flow margin | -104.2% | - | -35.4% | -778.8% | -1137.1% | -1100.1% | -1663.1% | -758.9% |
| Return on equity | - | - | - | - | -175.7% | -47.7% | - | -213.1% |
| Return on assets | -35.4% | -101.1% | -42.3% | -95.4% | -46.2% | -25.1% | -90.6% | -58.8% |
| Current ratio | 1.09 | 1.04 | 1.75 | 1.38 | 2.53 | 6.58 | 3.22 | 3.50 |
Source: XBRL data Nanobiotix S.A. files with the SEC, latest filing dated Mar 31, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
NBTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NBTX | €32.59M | - | -€23.96M | -73.5% | $1.63B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
NBTX FAQ
7 questionsWhat is NBTX revenue?
Nanobiotix S.A. (NBTX) reported €32.59M of revenue for fiscal 2025 (ended Dec 31, 2025).Is NBTX profitable?
No. Nanobiotix S.A. reported a net loss of €23.96M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does NBTX have?
Nanobiotix S.A. reported €52.75M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is NBTX free cash flow?
Nanobiotix S.A. generated -€33.96M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -€33.42M less capital expenditures.What is NBTX earnings per share?
Diluted earnings per share were -€0.50 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did NBTX last report financial results?
The latest statements here come from Nanobiotix S.A.'s 20-F filed on Mar 31, 2026, covering the period ended Dec 31, 2025.Where does this NBTX financial data come from?
Quantisnow builds these statements from the structured XBRL data Nanobiotix S.A. files with the SEC. It is provided for information only and is not investment advice.